PSMB9 and nasopharyngeal carcinoma: Peptide vaccines, which contain one of two different LMP2 peptides in Montanide ISA-51 adjuvant were tested in a phase I trial in patients with nasopharyngeal carcinoma that are either HLA-A*1101 or HLA-A*2402; results have not been reported (ClinicalTrials.gov NCT00078494).